EA201591513A1 - Терапевтическое применение антител к vegfr1 (варианты) - Google Patents

Терапевтическое применение антител к vegfr1 (варианты)

Info

Publication number
EA201591513A1
EA201591513A1 EA201591513A EA201591513A EA201591513A1 EA 201591513 A1 EA201591513 A1 EA 201591513A1 EA 201591513 A EA201591513 A EA 201591513A EA 201591513 A EA201591513 A EA 201591513A EA 201591513 A1 EA201591513 A1 EA 201591513A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vegfr1
antibodies
options
therapeutic application
therapeutic
Prior art date
Application number
EA201591513A
Other languages
English (en)
Inventor
Мэтью Дуглас Брейер
Лин Лю
Чжунхуа Ци
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201591513A1 publication Critical patent/EA201591513A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к способам применения антител к VEGFR1 для лечения хронической болезни почек.
EA201591513A 2013-03-15 2014-03-11 Терапевтическое применение антител к vegfr1 (варианты) EA201591513A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788870P 2013-03-15 2013-03-15
PCT/US2014/022925 WO2014150314A1 (en) 2013-03-15 2014-03-11 Therapeutic uses for vegfr1 antibodies

Publications (1)

Publication Number Publication Date
EA201591513A1 true EA201591513A1 (ru) 2016-01-29

Family

ID=50680115

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591513A EA201591513A1 (ru) 2013-03-15 2014-03-11 Терапевтическое применение антител к vegfr1 (варианты)

Country Status (16)

Country Link
US (1) US9670284B2 (ru)
EP (1) EP2970480A1 (ru)
JP (1) JP2017125013A (ru)
KR (1) KR20150119161A (ru)
CN (1) CN105102481A (ru)
AR (1) AR094919A1 (ru)
AU (1) AU2014237300B2 (ru)
BR (1) BR112015020199A2 (ru)
CA (1) CA2901509A1 (ru)
EA (1) EA201591513A1 (ru)
HK (1) HK1212713A1 (ru)
IL (1) IL241434A0 (ru)
MX (1) MX2015013066A (ru)
SG (1) SG11201507674UA (ru)
TW (1) TW201517916A (ru)
WO (1) WO2014150314A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41094A (fr) 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
EP3241844B1 (en) * 2014-12-03 2021-04-21 Aimed Bio Inc. Antibody against neuropilin 1 and use thereof
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
CN107690335A (zh) 2015-04-07 2018-02-13 夏尔人类遗传性治疗公司 治疗支气管肺发育不良的抗flt‑1抗体
EP4063390A1 (en) 2015-04-07 2022-09-28 Takeda Pharmaceutical Company Limited Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
EP3467508A4 (en) * 2016-06-03 2020-04-29 Samsung Life Public Welfare Foundation ANTI-NRP1 ANTIBODY SCREENING METHOD
AU2022331414A1 (en) * 2021-08-16 2024-04-04 Janssen Biotech, Inc. Anti-vegfr1 antibodies and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523457T3 (es) * 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
JP2013532152A (ja) * 2010-06-15 2013-08-15 メドジェニクス・メディカル・イスラエル・リミテッド 長期持続性の医薬製剤

Also Published As

Publication number Publication date
IL241434A0 (en) 2015-11-30
WO2014150314A1 (en) 2014-09-25
HK1212713A1 (zh) 2016-06-17
AU2014237300A1 (en) 2015-08-20
JP2017125013A (ja) 2017-07-20
US20140271675A1 (en) 2014-09-18
EP2970480A1 (en) 2016-01-20
MX2015013066A (es) 2016-09-21
JP6140841B2 (ja) 2017-05-31
TW201517916A (zh) 2015-05-16
CA2901509A1 (en) 2014-09-25
US9670284B2 (en) 2017-06-06
SG11201507674UA (en) 2015-10-29
BR112015020199A2 (pt) 2017-10-10
KR20150119161A (ko) 2015-10-23
JP2016511758A (ja) 2016-04-21
AU2014237300B2 (en) 2017-06-01
AR094919A1 (es) 2015-09-09
CN105102481A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
EA201690087A1 (ru) Новые квиназолиноны как ингибиторы бромодомена
DK2958945T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til behandling af cancer
DK3043816T3 (da) Anti-b7-h1-antistoffer til behandling af tumorer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201400178A1 (ru) Лечение рака молочной железы
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201692534A1 (ru) Способы лечения гипотонии